Sprout Pharmaceuticals Announces Release of Abstract Reporting Positive Interim Results for Flibanserin in Breast Cancer Patients Suffering from Low Libido for Poster Discussion at 2023 ASCO Annual Meeting

Posted on by

70% of women diagnosed with breast cancer report having sexual dysfunction, this includes disorders of sexual desire and sexual response. RALEIGH, N.C., June 2, 2023 /PRNewswire/ — Sprout Pharmaceuticals, Inc. a pharmaceutical company specializing in women’s sexual health today announced…

Posted in UncategorizedTagged
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.